{"name": "NeuroPhage Pharmaceuticals",
 "permalink": "neurophage-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/neurophage-pharmaceuticals",
 "homepage_url": "http://www.neurophage.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@neurophage.com",
 "phone_number": "617-714-5468",
 "description": "",
 "created_at": "Wed Mar 02 04:10:54 UTC 2011",
 "updated_at": "Tue May 07 11:54:37 UTC 2013",
 "overview": "\u003Cp\u003ENeuroPhage Pharmaceuticals, Inc., a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer\u2019s, Parkinson\u2019s, Huntington\u2019s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer\u2019s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       62],
      "assets/images/resized/0012/4531/124531v1-max-150x150.png"],
     [[203,
       84],
      "assets/images/resized/0012/4531/124531v1-max-250x250.png"],
     [[203,
       84],
      "assets/images/resized/0012/4531/124531v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Jonathan",
      "last_name": "Solomon",
      "permalink": "jonathan-solomon",
      "image": null}},
   {"is_past": true,
    "title": "Strategic Advisor",
    "person":
     {"first_name": "David",
      "last_name": "Neafus",
      "permalink": "david-neafus-2",
      "image":
       {"available_sizes":
         [[[118,
            118],
           "assets/images/resized/0027/1865/271865v1-max-150x150.png"],
          [[118,
            118],
           "assets/images/resized/0027/1865/271865v1-max-250x250.png"],
          [[118,
            118],
           "assets/images/resized/0027/1865/271865v1-max-450x450.png"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$27.8M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.neurophage.com/news.html",
    "source_description": "NeuroPhage Pharmaceuticals closes $12.4M Series B round",
    "raised_amount": 12400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 3,
    "funded_day": 1,
    "investments":
     [{"company":
        {"name": "Shire",
         "permalink": "shire",
         "image":
          {"available_sizes":
            [[[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-150x150.png"],
             [[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-250x250.png"],
             [[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-450x450.png"]],
           "attribution": null}},
       "financial_org": null,
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "M\u00c3\u00a9rieux D\u00c3\u00a9veloppement",
         "permalink": "mrieux-dveloppement",
         "image": null},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://www.finsmes.com/2012/03/neurophage-pharmaceuticals-raises-9-0m-series-b-1-funding.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "NeuroPhage Pharmaceuticals Raises $9.0M in Series B-1 Funding",
    "raised_amount": 9000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 3,
    "funded_day": 8,
    "investments":
     [{"company": null,
       "financial_org": null,
       "person":
        {"first_name": "Michael",
         "last_name": "Grundman",
         "permalink": "michael-grundman",
         "image": null}}]},
   {"round_code": "private_equity",
    "source_url": "http://www.finsmes.com/2013/05/neurophage-pharmaceuticals-raises-6-4m-equity-financing.html",
    "source_description": "NeuroPhage Pharmaceuticals Raises $6.4M in Equity Financing",
    "raised_amount": 6400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 5,
    "funded_day": 6,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Merieux Developpement",
         "permalink": "merieux-developpement",
         "image":
          {"available_sizes":
            [[[150,
               55],
              "assets/images/resized/0021/7382/217382v1-max-150x150.jpg"],
             [[250,
               92],
              "assets/images/resized/0021/7382/217382v1-max-250x250.jpg"],
             [[291,
               108],
              "assets/images/resized/0021/7382/217382v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company":
        {"name": "Shire",
         "permalink": "shire",
         "image":
          {"available_sizes":
            [[[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-150x150.png"],
             [[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-250x250.png"],
             [[150,
               44],
              "assets/images/resized/0009/6378/96378v1-max-450x450.png"]],
           "attribution": null}},
       "financial_org": null,
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "222 Third Street",
    "address2": "Suite 3120",
    "zip_code": "02142 ",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "closed a $12.4M Series B round",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 2,
    "source_url": "http://www.masshightech.com/stories/2011/02/28/daily45-New-NeuroPhage-funding-to-back-move-to-Alzheimers-trial.html",
    "source_text": null,
    "source_description": "New NeuroPhage funding to back move to Alzheimer's trial",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "NeuroPhage Pharmaceuticals",
      "permalink": "neurophage-pharmaceuticals"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}